What the FDA labels say about taking them together
Cholestyramine and maralixibat
Maralixibat's FDA label of April 10, 2025 names cholestyramine in its drug interactions section; the cholestyramine label PlainMeds reads does not name maralixibat.
Check it at the source: the cholestyramine FDA label on DailyMed (effective August 20, 2026, AiPing Pharmaceutical, Inc.); the maralixibat FDA label on DailyMed (effective April 10, 2025, Mirum Pharmaceuticals Inc.).
What does the cholestyramine label say about maralixibat?
Cholestyramine's label (effective August 20, 2026) does not name maralixibat in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Cholestyramine), AiPing Pharmaceutical, Inc., effective August 20, 2026 (SPL set 214ea05f-de81-4026-9df9-4ce3820668ee), via openFDA; the full label on DailyMed
What does the maralixibat label say about cholestyramine?
Maralixibat label, drug interactionsAdminister LIVMARLI at least 4 hours before or 4 hours after administration of bile acid binding resins (e.g., cholestyramine, colesevelam, or colestipol).
Source: FDA drug label (Livmarli), Mirum Pharmaceuticals Inc., effective April 10, 2025 (SPL set 64000394-1ef6-4e76-8ba8-11f25ba1b167), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Cholestyramine | Maralixibat | |
|---|---|---|
| Labeled for | High cholesterol | n/a |
| Boxed warning | No | No |
| Pharmacy cost (NADAC) | $0.834 per packet Cholestyramine packet | n/a |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once